Why Do Patients Switch from Humira to Cosentyx?
Patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis often switch from Humira (adalimumab) to Cosentyx (secukinumab) due to better efficacy in clearing skin and joint symptoms. In head-to-head trials like CLEAR, 86% of psoriasis patients on Cosentyx achieved PASI 90 skin clearance at week 16, compared to 69% on Humira [1]. Real-world surveys show 70-80% of switchers report improved skin clearance and fewer flares [2].
Easier Dosing and Self-Injection Experience
Cosentyx requires only four injections in the first month, then one every four weeks, versus Humira's biweekly dosing after loading. Patients cite less needle fatigue and simpler routines; a 2023 patient forum analysis found 65% preferred Cosentyx's autoinjector for quicker, less painful administration [3].
Fewer and Milder Infections
Both drugs suppress TNF or IL-17, but Cosentyx shows lower serious infection rates (2.1% vs. 3.5% for Humira in long-term data). Patients report fewer upper respiratory issues and candida infections with Cosentyx, especially in head-to-neck psoriasis where Humira triggered more flares [1][4].
Better Long-Term Joint Relief
For axial spondyloarthritis, Cosentyx delivers faster pain reduction—50% improvement in ASAS40 response by week 16 versus Humira's slower onset. Patient reviews highlight sustained mobility gains, with 62% preferring it for morning stiffness [5].
Cost and Access After Switching
Once on Cosentyx, copays average $20-50/month with manufacturer savings cards, similar to Humira, but switches often stem from insurance prior authorizations favoring Cosentyx as a newer IL-17 inhibitor. Biosimilar Humira entry since 2023 has lowered its price, yet Cosentyx loyalty persists for efficacy [6].
[1]: CLEAR trial, Lancet 2015
[2]: National Psoriasis Foundation patient survey, 2022
[3]: [Drugs.com user reviews comparison](https://www.drugs.com/comments/adalimumab/humira-for-psoriasis.html vs. secukinumab/cosentyx)
[4]: FDA labels, Cosentyx vs. Humira adverse events
[5]: PRECISION trial, Annals Rheum Dis 2018
[6]: GoodRx pricing data, 2024